A Study to Compare Eutropin Formulations in Healthy Volunteers for Bioavailability, Safety, and Tolerability
← catalyst calendarSponsored by LG Chem (industry) · 051910.KS — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Other
Enrollment
48actual
Sites
1
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-13 | actual | When the study began enrolling |
| Primary completion | 2025-04-15 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-04-15 | actual | The whole study's end, after follow-up |
| First posted | 2024-12-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-04-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Drug: Test Drug (Eutropin Catridge, 48IU/Cartridge) — also filed as T, Test Drug
- Drug: Reference Drug (Eutropin, 4 IU/vial) — also filed as R, Reference Drug
Primary outcome
what the primary-completion date above is the date OFAUClast of somatropin
measured 0 to 24 hours post-dose
Permalink · 051910.KS's whole pipeline · Catalyst calendar · Every registered study · What changed